By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

sanofi pasteur, Acambis Campus 

38 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-761-4200 Fax: 617-464-1742


SEARCH JOBS

Acambis is a leading developer of vaccines to prevent and treat infectious diseases. Recognized internationally as the leading producer of smallpox vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use stockpiles of this investigational vaccine for the US Government and other governments around the world. In January 2006, Acambis submitted the first portion of a Biologics License Application with the FDA to seek licensure for the vaccine and expects a decision by the FDA by the end of the year. Acambis is also developing an attenuated smallpox vaccine, MVA3000, under contracts with the US National Institutes of Health.

Acambis’ Miami-based subsidiary Berna Products Corporation markets Vivotif®, the world's only licensed oral typhoid vaccine, in North America. The company’s investigational vaccine against Japanese encephalitis, ChimeriVax-JE, is undergoing Phase 3 clinical testing. Acambis also has the most advanced investigational vaccine against the West Nile virus, which has spread to 48 states in the last six years, and a vaccine against Clostridium difficile bacteria, a leading cause of hospital-acquired infections.

Acambis is based in Cambridge, UK and Cambridge, Massachusetts, with operations in Canton, Massachusetts; Rockville, Maryland; and Miami, Florida. We invite you to learn more about Acambis and our employment opportunities at www.acambis.com.

Last Updated: 02-15-2006

Key Statistics


Email: acambis@acambis.com
Ownership: Public

Web Site: sanofi pasteur, Acambis Campus
Employees:
Symbol: ACAM
 



Industry
Biotechnology






Company News
Vivalis Grants Research License to Acambis (ACAM) to Evaluate E B66(R) Cell Line for Viral Vaccines Production 7/9/2008 8:38:59 AM
Crucell N.V. (CRXL) Announces PER.C6(R) Licensing Agreement with Acambis (ACAM) 11/20/2007 4:05:33 PM
Acambis (ACAM) Joins Forces With Sanofi Pasteur (SASY.PA) to Develop West Nile Virus Vaccine 11/13/2007 7:08:08 AM
Acambis (ACAM) Says Japanese Encephalitis Trial Positive 10/30/2006 3:17:35 PM
Acambis PLC (ACAM) Release: Research Update 9/12/2006 11:06:16 AM
Acambis PLC (ACAM) - Acambis (ACAM) Wins MVA Case 9/7/2006 4:00:34 PM
Peter Fellner To Become New Chairman Of Acambis (ACAM) 7/12/2006 4:50:32 PM
BioSpace, Inc. And Massachusetts Biotechnology Council, Inc. Unveil 2006 Genetown™ Campaign 12/14/2005 6:22:26 PM
Cangene Corporation (CC:CNJ) Wins UK Government Contract With Acambis PLC (ACAM) For $14.4 Million 10/19/2005 5:12:12 PM
//-->